牛牛AI助理已提取核心訊息
On January 8, 2024, Moderna, Inc. released preliminary financial results for the fiscal year ended December 31, 2023, during its presentation at the 42nd Annual J.P. Morgan Healthcare Conference. The company reported unaudited product sales of approximately $6.7 billion, primarily from its COVID-19 vaccine, which included about $0.6 billion in deferred revenue from its collaboration with GAVI, The Vaccine Alliance. Moderna also disclosed that its cash, cash equivalents, and marketable securities exceeded $13 billion as of year-end 2023. The audit of the financial statements is still in progress, and the final figures will be presented on the earnings call scheduled for February 22, 2024. Moderna's CEO, Stéphane Bancel, highlighted the company's increase in U.S. COVID-19 market share to 48% and the upcoming launch of its second...Show More
On January 8, 2024, Moderna, Inc. released preliminary financial results for the fiscal year ended December 31, 2023, during its presentation at the 42nd Annual J.P. Morgan Healthcare Conference. The company reported unaudited product sales of approximately $6.7 billion, primarily from its COVID-19 vaccine, which included about $0.6 billion in deferred revenue from its collaboration with GAVI, The Vaccine Alliance. Moderna also disclosed that its cash, cash equivalents, and marketable securities exceeded $13 billion as of year-end 2023. The audit of the financial statements is still in progress, and the final figures will be presented on the earnings call scheduled for February 22, 2024. Moderna's CEO, Stéphane Bancel, highlighted the company's increase in U.S. COVID-19 market share to 48% and the upcoming launch of its second product, an RSV vaccine. The company anticipates regulatory approvals for the RSV vaccine in the first half of 2024. Moderna also outlined its financial framework for 2024-2026, projecting approximately $4 billion in product sales for 2024, with expectations of returning to sales growth in 2025 and breaking even in 2026. The company's pipeline includes nine late-stage programs with key milestones expected in the next two years, covering vaccines for respiratory syncytial virus, COVID-19, seasonal flu, and cytomegalovirus, as well as oncology therapeutics and treatments for rare diseases like propionic acidemia and methylmalonic acidemia.
2024年1月8日，Moderna, Inc.在第42屆摩根大通醫療年度會議上發佈了截至2023年12月31日的財年的初步財務業績。該公司報告稱，未經審計的產品銷售額約爲67億美元，主要來自其 COVID-19 疫苗，其中包括與全球疫苗免疫聯盟合作產生的約6億美元遞延收入。Moderna還透露，截至2023年底，其現金、現金等價物和有價證券已超過130億美元。財務報表的審計仍在進行中，最終數據將在定於2024年2月22日舉行的業績電話會議上公佈。Moderna首席執行官斯特凡·班塞爾強調了該公司在美國 COVID-19 的市場份額增加到48％，以及即將推出的第二款產品——呼吸道合胞病毒疫苗。該...展開全部
2024年1月8日，Moderna, Inc.在第42屆摩根大通醫療年度會議上發佈了截至2023年12月31日的財年的初步財務業績。該公司報告稱，未經審計的產品銷售額約爲67億美元，主要來自其 COVID-19 疫苗，其中包括與全球疫苗免疫聯盟合作產生的約6億美元遞延收入。Moderna還透露，截至2023年底，其現金、現金等價物和有價證券已超過130億美元。財務報表的審計仍在進行中，最終數據將在定於2024年2月22日舉行的業績電話會議上公佈。Moderna首席執行官斯特凡·班塞爾強調了該公司在美國 COVID-19 的市場份額增加到48％，以及即將推出的第二款產品——呼吸道合胞病毒疫苗。該公司預計，RSV疫苗將在2024年上半年獲得監管部門的批准。Moderna還概述了其2024-2026年的財務框架，預計2024年的產品銷售額將達到約40億美元，預計銷售額將在2025年恢復增長，並在2026年實現收支平衡。該公司的產品線包括九個後期項目，預計將在未來兩年內實現關鍵里程碑，涵蓋呼吸道合胞病毒、COVID-19、季節性流感和鉅細胞病毒疫苗，以及丙酸血癥和甲基丙二酸血癥等罕見疾病的腫瘤療法和治療。
有用
沒用